Greenup Street Wealth Management LLC Has $2.58 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Greenup Street Wealth Management LLC trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 2.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 11,132 shares of the medical research company’s stock after selling 303 shares during the quarter. Greenup Street Wealth Management LLC’s holdings in IQVIA were worth $2,576,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of IQV. Jag Capital Management LLC boosted its holdings in shares of IQVIA by 0.4% in the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock valued at $2,638,000 after purchasing an additional 49 shares in the last quarter. Laurel Wealth Advisors LLC raised its stake in IQVIA by 1.1% during the third quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock worth $927,000 after acquiring an additional 50 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of IQVIA by 18.1% in the 3rd quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock valued at $68,000 after purchasing an additional 53 shares in the last quarter. Private Advisor Group LLC grew its holdings in shares of IQVIA by 1.2% during the 3rd quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock valued at $948,000 after purchasing an additional 56 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. lifted its stake in IQVIA by 1.6% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $702,000 after purchasing an additional 56 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.6 %

Shares of NYSE:IQV traded down $3.82 during mid-day trading on Friday, hitting $231.18. The company had a trading volume of 723,943 shares, compared to its average volume of 932,073. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The firm has a fifty day moving average price of $239.90 and a 200 day moving average price of $227.17. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The company has a market capitalization of $42.12 billion, a PE ratio of 31.58, a price-to-earnings-growth ratio of 2.36 and a beta of 1.52.

IQVIA (NYSE:IQVGet Free Report) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The firm had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same period last year, the firm earned $2.54 earnings per share. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.1 EPS for the current year.

Insider Activity

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

IQV has been the subject of several research analyst reports. Guggenheim downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. BTIG Research started coverage on shares of IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective for the company. SVB Leerink initiated coverage on shares of IQVIA in a report on Monday, February 26th. They set an “outperform” rating and a $290.00 target price on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Finally, Evercore ISI reduced their price objective on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $257.57.

Read Our Latest Analysis on IQV

About IQVIA

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Articles

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.